科济药业近日公布了2024年度业绩报告,显示公司全年收益约为人民币3.94亿元,主要来源于核心产品赛恺泽的销售。该数据以出厂价格为基准计算,而非终端市场价。报告期内,公司实现毛利约1.48亿元,销售成本控制在2.47亿元以内,展现出良好的运营效率。截至2024年底,科济药业持有现金及银行结余约14.79亿元,预计到2025年末,现金及现金等价物和存款将保持在10.80亿元以上。这一系列数据表明,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.